Gagnier Joel, Boon Heather, Rochon Paula, Barnes Joanne, Moher David, Bombardier Claire
Department of Health Policy, Management and Evaluation, Department of Medicine, Univerity of Toronto, Toronto, Canada.
Explore (NY). 2006 Mar;2(2):143-9. doi: 10.1016/j.explore.2005.12.003.
Given that herbal medicinal products are widely used, vary greatly in content and quality, and are actively tested in randomized controlled trials (RCTs), such RCTs must clearly report the specifics of the intervention.
Our objective was to develop recommendations for reporting RCTs of herbal medicine interventions.
We identified and invited potential participants with expertise in clinical trial methodology, clinical trial reporting, pharmacognosy, herbal medicinal products, medical statistics, and/or herbal product manufacturing to participate in phone calls and a consensus meeting. Three phases were conducted: (1) Premeeting item generation via telephone calls, (2) Consensus meeting, and (3) Postmeeting feedback. Sixteen experts participated in premeeting phone calls for item generation, and 14 participants attended a consensus meeting in Toronto, Ontario, Canada, in June of 2004. During the consensus meeting, a modified Delphi technique was used to aid discussion and debate of information required for reporting RCTs of herbal medicines.
After extensive discussion, the group decided that context-specific elaborations of nine Consolidated Standards of Reporting Trials (CONSORT) items to RCTs of herbal medicines were necessary: Item 1 (Title and Abstract), 2 (Background), 3 (Participants), 4 (Interventions), 6 (Outcomes), 15 (Baseline data), 20 (Interpretation), 21 (Generalizability), and 22 (Overall evidence).
The elaboration of item 4 of the CONSORT statement outlines specific information required for complete reporting of the herbal medicine intervention. The reporting suggestions presented will support clinical trialists, editors, and reviewers in reporting and reviewing RCTs of herbal medicines and readers in interpreting the results.
鉴于草药产品应用广泛,其成分和质量差异极大,且正在随机对照试验(RCT)中接受积极测试,此类RCT必须清晰报告干预措施的具体细节。
我们的目的是制定草药干预措施RCT报告的建议。
我们识别并邀请了在临床试验方法学、临床试验报告、生药学、草药产品、医学统计学和/或草药产品制造方面具有专业知识的潜在参与者参加电话会议和共识会议。共进行了三个阶段:(1)通过电话会议生成会前项目,(2)共识会议,(3)会后反馈。16位专家参加了会前项目生成电话会议,14位参与者于2004年6月在加拿大多伦多参加了共识会议。在共识会议期间,采用了改良的德尔菲技术来辅助讨论和辩论草药RCT报告所需的信息。
经过广泛讨论,小组决定有必要针对草药RCT对九条统一报告标准(CONSORT)项目进行特定背景的阐述:项目1(标题和摘要)、2(背景)、3(参与者)、4(干预措施)、6(结局)、15(基线数据)、20(解读)、21(可推广性)和22(总体证据)。
CONSORT声明项目4的阐述概述了完整报告草药干预措施所需的具体信息。所提出的报告建议将支持临床试验人员、编辑和审稿人报告和审核草药RCT,以及读者解读结果。